Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: An update

International Journal of Andrology

Volumn 34, Issue 4 PART 2, 2011, Pages

  Koychev, D ^a   Oechsle, K ^a   Bokemeyer, C ^a   Honecker, F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cancer; Testicular neoplasms; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; AZACITIDINE; B RAF KINASE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEOXYCYTIDINE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; LENALIDOMIDE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; THALIDOMIDE; THIOTEPA; VINBLASTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; DRUG FATALITY; DRUG MEGADOSE; GENE MUTATION; GERM CELL TUMOR; HUMAN; METHYLATION; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SEMINOMA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; TESTICULAR NEOPLASMS;

EID: 79960851806     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2011.01145.x     Document Type: Review

References (72)

1. Albers P, Ganz A, Hannig E, Miersch WD & Muller SC. (2000) Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol, 164, 381-384.
2. Albers P, Weissbach L, Krege S, Kliesch S, Hartmann M, Heidenreich A, Walz P, Kuczyk M & Fimmers R. (2004) Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the german testicular cancer study group. J Urol, 171, 1835-1838.
3. Beck SD, Foster RS, Bihrle R, Cheng L, Ulbright TM & Donohue JP. (2005a) Impact of the number of positive lymph nodes on disease-free survival in patients with pathological stage b1 nonseminomatous germ cell tumor. J Urol, 174, 143-145.
4. Beck SD, Foster RS, Bihrle R, Einhorn LH & Donohue JP. (2005b) Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. Urol Oncol, 23, 423-430.
5. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP et al. (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol, 14, 2638-2645.
6. Beyer J, Stenning S, Gerl A, Fossa S & Siegert W. (2002) High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol, 13, 599-605.
7. Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E & Spinella MJ. (2009) High DNA methyltransferase 3b expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res, 69, 9360-9366.
8. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J & Souchon R. (1994) Preliminary results of a phase i/ii trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol, 120, 754-757.
9. Bokemeyer C, Gerl A, Schoffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ & Kanz L. (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol, 17, 512-516.
10. Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Bohlke I & Kollmannsberger C. (2008) Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the german testicular cancer study group. Ann Oncol, 19, 448-453.
11. Bosl GJ & Motzer RJ. (1997) Testicular germ-cell cancer. N Engl J Med, 337, 242-253.
12. Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O et al. (2009) Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res, 15, 3384-3395.
13. Coffey J, Linger R, Pugh J, Dudakia D, Sokal M, Easton DF, Timothy Bishop D, Stratton M, Huddart R & Rapley EA. (2008) Somatic kit mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosom Cancer, 47, 34-42.
14. Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER Jr, Einhorn LH, Roth BJ & Donohue JP. (1997) Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology, 50, 957-962.
15. Einhorn LH, Pennington K & McClean J. (1990) Phase ii trial of daily oral vp-16 in refractory small cell lung cancer: a hoosier oncology group study. Semin Oncol, 17, 32-35.
16. Einhorn LH, Stender MJ & Williams SD. (1999) Phase ii trial of gemcitabine in refractory germ cell tumors. J Clin Oncol, 17, 509-511.
17. Einhorn LH, Brames MJ, Heinrich MC, Corless CL & Madani A. (2006) Phase ii study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing kit. Am J Clin Oncol, 29, 12-13.
18. Einhorn LH, Brames MJ, Juliar B & Williams SD. (2007a) Phase ii study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol, 25, 513-516.
19. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM & Abonour R. (2007b) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med, 357, 340-348.
20. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C et al. (2010) A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer, 116, 4043-4053.
21. Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ & Motzer RJ. (2010) Phase ii trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs, 28, 523-528.
22. Flaherty KT & McArthur G. (2010) Braf, a target in melanoma: implications for solid tumor drug development. Cancer, 116, 4902-4913.
23. Geldart TR, Gale J, McKendrick J, Kirby J & Mead G (2006) Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int, 98, 353-358.
24. Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA & Horwich A. (2002) Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer, 94, 1668-1676.
25. Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ et al. (2009) Microsatellite instability, mismatch repair deficiency, and braf mutation in treatment-resistant germ cell tumors. J Clin Oncol, 27, 2129-2136.
26. Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A & Heinrich MC. (2004) Kit mutations are common in testicular seminomas. Am J Pathol, 164, 305-313.
27. Kollmannsberger C, Honecker F & Bokemeyer C. (2008) Pharmacotherapy of relapsed metastatic testicular cancer. Expert Opin Pharmacother, 9, 2259-2272.
28. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, Bosl GJ & Motzer RJ. (2005) Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol, 23, 6549-6555.
29. Korkola JE, Houldsworth J, Bosl GJ & Chaganti RS. (2009a) Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin. BJU Int, 104, 1334-1338.
30. Korkola JE, Houldsworth J, Feldman DR, Olshen AB, Qin LX, Patil S, Reuter VE, Bosl GJ & Chaganti RS. (2009b) Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol, 27, 5240-5247.
31. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F et al. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the european germ cell cancer consensus group (egcccg): part ii. Eur Urol, 53, 497-513.
32. Kuczyk MA, Bokemeyer C, Kollmannsberger C, Corvin S, Anastasiadis A, Machtens S et al. (2004) Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience. World J Urol, 22, 55-59.
33. Loehrer PJ Sr, Einhorn LH & Williams SD. (1986) Vp-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol, 4, 528-536.
34. Loehrer PJ Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA & Einhorn LH. (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med, 109, 540-546.
35. Loehrer PJ Sr, Gonin R, Nichols CR, Weathers T & Einhorn LH. (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol, 16, 2500-2504.
36. Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE et al. (2007) Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the german testicular cancer study group. J Clin Oncol, 25, 2778-2784.
37. Lorch A, Neubauer A, Hackenthal M, Dieing A, Hartmann JT, Rick O, Bokemeyer C & Beyer J. (2010a) High-dose chemotherapy (hdct) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol, 21, 820-825.
38. Lorch A, Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, DeGiorgi U, Flechon A, Margolin KA & Beyer J. (2010b) Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: a retrospective study in 1594 patients. J Clin Oncol 28, 15s, (suppl; abstr 4513)
39. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE & Gerharz CD. (2002) Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer, 100, 30-36.
40. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH & Bokemeyer C. (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res, 9, 767-773.
41. McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V & Motzer RJ. (1997) Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol, 15, 2559-2563.
42. Mead GM & Stenning SP. (1997) The international germ cell consensus classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol), 9, 207-209.
43. Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJ, Cook PA, Stenning SP & Mason M. (2005) A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer, 93, 178-184.
44. Miller KD, Loehrer PJ, Gonin R & Einhorn LH. (1997) Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol, 15, 1427-1431.
45. Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ & Dmitrovsky E. (1995) All-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase ii trial. Cancer, 76, 680-686.
46. Motzer RJ, Cooper K, Geller NL, Pfister DG, Lin SY, Bajorin D, et al. (1990) Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. Cancer, 65, 2465-2470.
47. Motzer RJ, Geller NL, Tan CC, Herr H, Morse M, Fair W, Sheinfeld J, Sogani P, Russo P & Bosl GJ. (1991) Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979-1989). Cancer, 67, 1305-1310.
48. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D & Bosl GJ. (2000) Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol, 18, 2413-2418.
49. Muller-Tidow C, Schwable J, Steffen B, Tidow N, Brandt B, Becker K et al. (2004) High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res, 10, 1241-1249.
50. Netto GJ, Nakai Y, Nakayama M, Jadallah S, Toubaji A, Nonomura N et al. (2008) Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. Mod Pathol, 21, 1337-1344.
51. Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ et al. (1989) Dose-intensive chemotherapy in refractory germ cell cancer - a phase i/ii trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol, 7, 932-939.
52. Nicolato A, Ria A, Foroni R, Manno P, Alessandrini F, Sava T et al. (2005) Gamma knife radiosurgery in brain metastases from testicular tumors. Med Oncol, 22, 45-56.
53. Oechsle K, Kollmannsberger C, Honecker F, Boehlke I & Bokemeyer C. (2008) Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. Eur J Cancer, 44, 1663-1669.
54. Oechsle K, Bokemeyer C & Honecker F. (2010a) Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. J Cancer Res Clin Oncol, 136, 165-167.
55. Oechsle K, Kollmannsberger C, Honecker F, Mayer F, Waller CF, Bohlke I & Bokemeyer C. (2010b) Long term outcome in patients with cisplatin-refractory or multiply relapsed germ cell tumors following treatment with gemcitabine and oxaliplatin ± paclitaxel. J Clin Oncol 28, 15s, (suppl; abstr 4585)
56. Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, et al. (2011) Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol, [Epub ahead of publication].
57. Pedersini R, Vattemi E, Mazzoleni G & Graiff C. (2007) Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-kit. Lancet Oncol, 8, 1039-1040.
58. Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R et al. (2005) A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol, 16, 1152-1159.
59. Quagliana JM, O'Bryan RM, Baker L, Gottlieb J, Morrison FS, Eyre HJ, Tucker WG & Costanzi J. (1977) Phase ii study of 5-azacytidine in solid tumors. Cancer Treat Rep, 61, 51-54.
60. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, et al. (2001) Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol, 19, 81-88.
61. Rick O, Bokemeyer C, Weinknecht S, Schirren J, Pottek T, Hartmann JT et al. (2004) Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol, 22, 3713-3719.
62. Rick O, Braun T, Siegert W & Beyer J. (2006) Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer, 42, 1775-1779.
63. Roth BJ, Elson P, Sledge GW Jr, Einhorn LH & Trump DL. (1993) 5-azacytidine (nsc 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group. Invest New Drugs, 11, 201-202.
64. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol, 15, 1377-1399.
65. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ & Huhn D. (1994) High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol, 12, 1223-1231.
66. Span PN, Tjan-Heijnen VC, Manders P, van Tienoven D, Lehr J & Sweep FC. (2006) High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat, 98, 223-230.
67. Terakawa T, Miyake H, Muramaki M, Takenaka A & Fujisawa M. (2010) Salvage chemotherapy with methotrexate, etoposide and actinomycin d in men with metastatic nonseminomatous germ cell tumors with a choriocarcinoma component: a preliminary report. Int J Urol, 17, 881-885.
68. The International Prognostic Factors Study Group. (2010) Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol, 28, 4906-4911.
69. Vaena DA, Abonour R & Einhorn LH. (2003) Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol, 21, 4100-4104.
70. Velasco A, Corvalan A, Wistuba II, Riquelme E, Chuaqui R, Majerson A & Leach FS. (2008) Mismatch repair expression in testicular cancer predicts recurrence and survival. Int J Cancer, 122, 1774-1777.
71. Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M, Reuter V, Bajorin DF, Bosl GJ & Motzer RJ. (2002) Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol, 20, 297-301.
72. Wermann H, Stoop H, Gillis AJ, Honecker F, van Gurp RJ, Ammerpohl O, Richter J, Oosterhuis JW, Bokemeyer C & Looijenga LH. (2010) Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J Pathol, 221, 433-442.